QoL in Pts With MF: Highlighting the Need for New Agents

Jeanne Palmer

EHA® 2023 Insights: "Disease-Modifying Activity of Navtemadlin Corre…

Insights from 2023 EHA® Annual Meeting

P. Vachhani

ASCO® 2023 Insights: "A Ph1 Trial of Dose-Adjusted EPOCH + Inotuzuma…

Insights from 2023 ASCO® Annual Meeting

N. Kopmar

ASCO® 2023 Insights: "Updated Results From XPORT-MF-034 - Selinexor …

Insights from 2023 ASCO® Annual Meeting

H. Ali

Unmet Needs in MF Treatment

Lindsay Rein

Management of MPNs for the Community Oncologist

Fred Hutchinson Cancer Center

H. Deeg

Updates on the Treatment of Myelofibrosis and FGFR-Mutated Myeloid N…

Indy Hematology Review

A. Fleischman

Cytopenic Myelofibrosis

Jeanne Palmer

Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway

Icahn School of Medicine at Mount Sinai

M. Kremyanskaya

Monitoring Patients With MF: When to Switch Treatment

Douglas Tremblay

Yale ASH Highlights - Myeloid Malignancies: Focus on MPNs

Yale Cancer Center

N. Podoltsev

Management of Clinical Manifestations in Myelofibrosis

Jeanne Palmer

Evolving Therapy of MF in 2022: JAK Inhibitors as Foundation

MedNews Week

R. Mesa

Advances in Myelofibrosis Treatment

Alessandro Vannucchi

Early Intervention in Myelofibrosis

SOHO 2022 Tenth Annual Meeting

A. Yacoub

Symptom Assessment in Myelofibrosis

Krisstina Gowin

How I Treat Symptom Burden in MPNs

Indy Hematology Review

R. Mesa